TNF-α和 RANKL 与类风湿关节炎的研究进展

摘要

Rheumatoid arthritis ( RA) is an autoimmune disease presented by progressive synovial inflammation , cartilage erosion and bone destruction.The members of tumor necrosis factor superfamily (TNFSF), especially tumor necrosis fac-tor-α(TNF-α)and receptor activator of NF-κB ligand (RANKL), contribute considerably to the inflammation and bone loss in RA.A few biological agents targeting TNFSF have been developed and widely used in the treatment of RA .This re-view aims to summarize the roles of TNF-αand RANKL in RA and the clinical effects of the antagonists .%类风湿关节炎（ RA）是一种以慢性侵蚀性关节炎为特征的自身免疫性疾病，伴随有慢性滑膜炎症及继发的关节软骨和骨质的破坏。肿瘤坏死因子超家族（ TNFSF）的成员，特别是肿瘤坏死因子-α（ TNF-α）和核因子-κB受体活化因子配体（ RANKL）在疾病的炎症和骨破坏过程中发挥着至关重要的作用。一些靶向于TNFSF的生物制剂已被开发应用于RA的治疗。综述了TNF-α和RANKL在类风湿关节炎中的作用以及靶向药物的治疗效果。